Association of hepatocyte growth factor promoter polymorphism with severity of interstitial lung disease in Japanese patients with systemic sclerosis

Arthritis and Rheumatism

Volumn 63, Issue 8, 2011, Pages 2465-2472

  Hoshino, Kana ^a   Satoh, Takashi ^a   Kawaguchi, Yasushi ^b   Kuwana, Masataka ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SCATTER FACTOR;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; EXON; FEMALE; FORCED VITAL CAPACITY; GEL MOBILITY SHIFT ASSAY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; INTERSTITIAL LUNG DISEASE; INTRON; JAPANESE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC SCLEROSIS; TRANSCRIPTION REGULATION;

ADULT; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 79961101947     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30415     Document Type: Article

References (28)

1. Agarwal SK, Tan FK, Arnett FC,. Genetics and genomic studies in scleroderma (systemic sclerosis). Rheum Dis Clin North Am 2008; 34: 17-40. (Pubitemid 351337628)
2. Varga J, Abraham D,. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67. (Pubitemid 46348510)
3. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999; 5: 226-30. (Pubitemid 29068532)
4. Kawaguchi Y, Harigai M, Hara M, Fukasawa C, Takagi K, Tanaka M, et al. Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis. J Rheumatol 2002; 29: 1877-83. (Pubitemid 34988696)
5. Mizuno S, Matsumoto K, Li MY, Nakamura T,. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J 2005; 19: 580-2. (Pubitemid 40471250)
6. Inoue T, Okada H, Kobayashi T, Watanabe Y, Kanno Y, Kopp JB, et al. Hepatocyte growth factor counteracts transforming growth factor-β1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice. FASEB J 2003; 17: 268-70.
7. Dai C, Liu Y,. Hepatocyte growth factor antagonizes the profibrotic action of TGF-β1 in mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J Am Soc Nephrol 2004; 15: 1402-12. (Pubitemid 38679665)
8. Kawaguchi Y, Harigai M, Fukasawa C, Hara M,. Increased levels of hepatocyte growth factor in sera of patients with systemic sclerosis. J Rheumatol 1999; 26: 1012-3. (Pubitemid 29195710)
9. McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisa JR, Goel N, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007; 57: 318-26. (Pubitemid 47164096)
10. Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA,. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998; 114; 801-7. (Pubitemid 28433744)
11. Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA Jr, Wright TM,. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 1999; 42: 465-74. (Pubitemid 29136094)
12. Bogatkevich GS, Ludwicka-Bradley A, Highland KB, Hant F, Nietert PJ, Singleton CB, et al. Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis. Arthritis Rheum 2007; 56: 2432-42. (Pubitemid 47173591)
13. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
14. Medsger TA Jr,. Systemic sclerosis (scleroderma), localized scleroderma, eosinophilic fasciitis and calcinosis. In: Arthritis and allied conditions: a textbook of rheumatology., McCarty DJ, editor. 11th ed. Philadelphia: Lea & Febiger; 1989. p. 1118-65.
15. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M,. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37: 75-83. (Pubitemid 24027696)
16. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 2159-67. (Pubitemid 29487010)
17. Takiuchi S, Mannami T, Miyata T, Kamide K, Tanaka C, Kokubo Y, et al. Identification of 21 single nucleotide polymorphisms in human hepatocyte growth factor gene and association with blood pressure and carotid atherosclerosis in the Japanese population. Atherosclerosis 2004; 173: 301-7. (Pubitemid 38469800)
18. Hirakawa M, Tanaka T, Hashimoto Y, Kuroda M, Takagi T, Nakamura Y,. JSNP: a database of common gene variations in the Japanese population. Nucleic Acids Res 2002; 30: 158-62. (Pubitemid 34679529)
19. Miyazawa K, Kitamura A, Kitamura N,. Structural organization and the transcription initiation site of the human hepatocyte growth factor gene. Biochemistry 1991; 30: 9170-6.
20. Schreiber E, Matthias P, Muller MM, Schaffner W,. Rapid detection of octamer binding proteins with 'mini-extracts,' prepared from a small number of cells. Nucleic Acids Res 1989; 17: 6419. (Pubitemid 19198635)
21. He Y, Casaccia-Bonnefil P,. The yin and yang of YY1 in the nervous system. J Neurochem 2008; 106: 1493-502.
22. Dohi M, Hasegawa T, Yamamoto K, Marshall BC,. Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis. Am J Respir Crit Care Med 2000; 162: 2302-7. (Pubitemid 32051704)
23. Mizuno S, Matsumoto K, Li MY, Nakamura T,. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J 2005; 19: 580-2. (Pubitemid 40471250)
24. Watanabe M, Ebina M, Orson FM, Nakamura A, Kubota K, Koinuma D, et al. Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis. Mol Ther 2005; 12: 58-67. (Pubitemid 40862357)
25. Gazdhar A, Fachinger P, van Leer C, Pierog J, Gugger M, Friis R, et al. Gene transfer of hepatocyte growth factor by electroporation reduces bleomycin-induced lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2007; 292: L529-36.
26. Jinnin M, Inn H, Mimura Y, Asano Y, Yamane K, Tamaki K,. Effects of hepatocyte growth factor on the expression of type I collagen and matrix metalloproteinase-1 on normal and scleroderma dermal fibroblasts. J Invest Dermatol 2005; 124: 324-30. (Pubitemid 40175878)
27. Mason RJ, Leslie CC, McCormick-Shannon K, Deterding RR, Nakamura T, Rubin JS, et al. Hepatocyte growth factor is a growth factor for rat alveolar type II cells. Am J Respir Cell Mol Biol 1994; 11: 561-7.
28. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29: 308-11. (Pubitemid 32054478)